Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:16:31.156Z.
Calculation as of: 2026-10-06T16:16:31.156Z.
Quote observation: 2026-10-06T16:15:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d6bd3278d76725a85d4cb05495e45b99d0fd89b23371e3701c8289362793e8f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Design Therapeutics, Inc.
Market Cap
$763.85M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$771.14M
EV/EBITDA Ratio
18.53x
TTM Avg
16.06x
3Y Avg
17.33x
5Y Avg
27.55x
Market Cap
$779.56M
EV/EBITDA Ratio
N/A
TTM Avg
14.36x
3Y Avg
6.18x
5Y Avg
6.18x
Market Cap
$781.61M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$744.43M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$789.07M
EV/EBITDA Ratio
N/A
TTM Avg
800.36x
3Y Avg
800.36x
5Y Avg
800.36x
Market Cap
$737.09M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $763.85M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $771.14M | 18.53x | 16.06x | 17.33x | 27.55x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $779.56M | N/A | 14.36x | 6.18x | 6.18x |
| Attovia Therapeutics, Inc. (ATTO)vs › | $781.61M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $744.43M | N/A | N/A | N/A | N/A |
| Sana Biotechnology, Inc. (SANA)vs › | $788.34M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $789.07M | N/A | 800.36x | 800.36x | 800.36x |
| Faeth Therapeutics, Inc. (FTH)vs › | $737.29M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $737.09M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $792.48M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
